Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment

Cancer Letters

Volumn 380, Issue 2, 2016, Pages 494-504

  Shi, Puyu ^a,b   Oh, You Take ^b   Zhang, Guojing ^b   Yao, Weilong ^b   Yue, Ping ^b   Li, Yikun ^b   Kanteti, Rajani ^c   Riehm, Jacob ^c   Salgia, Ravi ^d   Owonikoko, Taofeek K ^b   Ramalingam, Suresh S ^b   Chen, Mingwei ^a   Sun, Shi Yong ^b  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

AZD9291; Bim; EGFR; Erlotinib; Met; Resistance

Indexed keywords

CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; OSIMERTINIB; ROCILETINIB; SGX 523; TIVANTINIB; UNCLASSIFIED DRUG; ACRYLAMIDE DERIVATIVE; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SCATTER FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG CANCER CELL LINE; MET GENE; MONOTHERAPY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE; TUMOR VOLUME;

ACRYLAMIDES; ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE, NUDE; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84979306616     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.07.021     Document Type: Article

References (26)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J. Clin 65 (2015), 5–29.
2. [2] Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA Cancer J. Clin 65 (2015), 87–108.
3. [3] Tartarone, A., Lerose, R., Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance. Ther. Adv. Respir. Dis 9 (2015), 242–250.
4. [4] Juchum, M., Gunther, M., Laufer, S.A., Fighting cancer drug resistance: opportunities and challenges for mutation-specific EGFR inhibitors. Drug Resist. Updat 20 (2015), 10–28.
5. [5] Remon, J., Moran, T., Majem, M., Reguart, N., Dalmau, E., Marquez-Medina, D., et al. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. Cancer Treat. Rev 40 (2014), 93–101.
6. [6] Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007), 1039–1043.
7. [7] Suda, K., Murakami, I., Katayama, T., Tomizawa, K., Osada, H., Sekido, Y., et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin. Cancer Res 16 (2010), 5489–5498.
8. [8] Janne, P.A., Yang, J.C., Kim, D.W., Planchard, D., Ohe, Y., Ramalingam, S.S., et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med 372 (2015), 1689–1699.
9. [9] Sequist, L.V., Soria, J.C., Goldman, J.W., Wakelee, H.A., Gadgeel, S.M., Varga, A., et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med 372 (2015), 1700–1709.
10. [10] Govindan, R., Overcoming resistance to targeted therapy for lung cancer. N. Engl. J. Med 372 (2015), 1760–1761.
11. [11] Thress, K.S., Paweletz, C.P., Felip, E., Cho, B.C., Stetson, D., Dougherty, B., et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med 21 (2015), 560–562.
12. [12] Ercan, D., Choi, H.G., Yun, C.H., Capelletti, M., Xie, T., Eck, M.J., et al. EGFR mutations and resistance to irreversible pyrimidine based EGFR inhibitors. Clin. Cancer Res 21 (2015), 3913–3923.
13. [13] Niederst, M.J., Hu, H., Mulvey, H.E., Lockerman, E.L., Garcia, A.R., Piotrowska, Z., et al. The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res 21 (2015), 3924–3933.
14. [14] Ercan, D., Zejnullahu, K., Yonesaka, K., Xiao, Y., Capelletti, M., Rogers, A., et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29 (2010), 2346–2356.
15. [15] Li, Y., Fan, S., Koo, J., Yue, P., Chen, Z.G., Owonikoko, T.K., et al. Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biol. Ther 13 (2012), 272–280.
16. [16] Sun, S.Y., Yue, P., Dawson, M.I., Shroot, B., Michel, S., Lamph, W.W., et al. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res 57 (1997), 4931–4939.
17. [17] Wang, X., Hawk, N., Yue, P., Kauh, J., Ramalingam, S.S., Fu, H., et al. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol. Ther 7 (2008), 1952–1958.
18. [18] Yao, W., Yue, P., Zhang, G., Owonikoko, T.K., Khuri, F.R., Sun, S.Y., Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells. Cancer Lett 364 (2015), 70–78.
19. [19] Liu, X., Yue, P., Zhou, Z., Khuri, F.R., Sun, S.Y., Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J. Natl. Cancer Inst 96 (2004), 1769–1780.
20. [20] Luciano, F., Jacquel, A., Colosetti, P., Herrant, M., Cagnol, S., Pages, G., et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 22 (2003), 6785–6793.
21. [21] Ley, R., Balmanno, K., Hadfield, K., Weston, C., Cook, S.J., Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J. Biol. Chem 278 (2003), 18811–18816.
22. [22] Planchard, D., Loriot, Y., Andre, F., Gobert, A., Auger, N., Lacroix, L., et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann. Oncol 26 (2015), 2073–2078.
23. [23] Kim, T.M., Song, A., Kim, D.W., Kim, S., Ahn, Y.O., Keam, B., et al. Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor. J. Thorac. Oncol 10 (2015), 1736–1744.
24. [24] Ma, J., Lyu, H., Huang, J., Liu, B., Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol. Cancer, 13, 2014, 105.
25. [25] Costa, D.B., Halmos, B., Kumar, A., Schumer, S.T., Huberman, M.S., Boggon, T.J., et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 4 (2007), 1669–1679 discussion 1680.
26. [26] Gong, Y., Somwar, R., Politi, K., Balak, M., Chmielecki, J., Jiang, X., et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med, 4, 2007, e294.